New Immune-Boosting drug takes on Hard-to-Treat cancers
Disease control
Recruiting now
This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…
Phase: PHASE1 • Sponsor: Tizona Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC